Original Research

Published on 27 Jan 2023

Identification of thioredoxin-1 as a biomarker of lung cancer and evaluation of its prognostic value based on bioinformatics analysis

in Cancer Molecular Targets and Therapeutics

Xiaoting Liu
Xilin Dong
Yaxin Hu
Yanan Fang

Frontiers in Oncology

doi 10.3389/fonc.2023.1080237

2,464 views
1 citation

Review

Published on 26 Jan 2023

Synthetic lethal interactions of DEAD/H-box helicases as targets for cancer therapy

in Cancer Molecular Targets and Therapeutics

Ananna Bhadra Arna
Hardikkumar Patel
Ravi Shankar Singh
Frederick S. Vizeacoumar
Anthony Kusalik
Andrew Freywald
Franco J. Vizeacoumar
Yuliang Wu

Frontiers in Oncology

doi 10.3389/fonc.2022.1087989

5,284 views
2 citations

Original Research

Published on 26 Jan 2023

Application of ddPCR in detection of the status and abundance of EGFR T790M mutation in the plasma samples of non-small cell lung cancer patients

in Cancer Molecular Targets and Therapeutics

Hui Zhang
Yi Hu
Yan Wang
Xia Song
Ying Hu
Li Ma
Xinjie Yang
Kun Li
Na Qin
Jinghui Wang

Frontiers in Oncology

doi 10.3389/fonc.2022.942123

2,763 views
4 citations

Original Research

Published on 26 Jan 2023

HiRAND: A novel GCN semi-supervised deep learning-based framework for classification and feature selection in drug research and development

in Cancer Molecular Targets and Therapeutics

Yue Huang
Zhiwei Rong
Liuchao Zhang
Zhenyi Xu
Jianxin Ji
Jia He
Weisha Liu
Yan Hou
Kang Li

Frontiers in Oncology

doi 10.3389/fonc.2023.1047556

1,685 views

Original Research

Published on 26 Jan 2023

SLC-0111, an inhibitor of carbonic anhydrase IX, attenuates hepatoblastoma cell viability and migration

in Cancer Molecular Targets and Therapeutics

Katja Eloranta
Marjut Pihlajoki
Emmi Liljeström
Ruth Nousiainen
Tea Soini
Jouko Lohi
Stefano Cairo
David B. Wilson
Seppo Parkkila
Markku Heikinheimo

Frontiers in Oncology

doi 10.3389/fonc.2023.1118268

3,486 views
14 citations

Review

Published on 25 Jan 2023

Krüppel-like factors in tumors: Key regulators and therapeutic avenues

in Cancer Molecular Targets and Therapeutics

Yuchen Zhang
Chongjie Yao
Ziyong Ju
Danli Jiao
Dan Hu
Li Qi
Shimin Liu
Xueqing Wu
Chen Zhao

Frontiers in Oncology

doi 10.3389/fonc.2023.1080720

4,558 views
15 citations

Original Research

Published on 23 Jan 2023

GPBAR1 is associated with asynchronous bone metastasis and poor prognosis of hepatocellular carcinoma

in Cancer Molecular Targets and Therapeutics

Nan Chen
Jieqing Wang
Lei Zhou
Baiqiang Hu
Yinzhong Chen
Zhuangchen Zhu

Frontiers in Oncology

doi 10.3389/fonc.2022.1113785

1,680 views
2 citations

Review

Published on 23 Jan 2023

Cancel cancer: The immunotherapeutic potential of CD200/CD200R blockade

in Cancer Molecular Targets and Therapeutics

Deborah Choe
Dongwon Choi

Frontiers in Oncology

doi 10.3389/fonc.2023.1088038

6,348 views
10 citations

Review

Published on 23 Jan 2023

COMMD proteins function and their regulating roles in tumors

in Cancer Molecular Targets and Therapeutics

Guangqiang You
Chen Zhou
Lei Wang
Zefeng Liu
He Fang
Xiaoxao Yao
Xuewen Zhang

Frontiers in Oncology

doi 10.3389/fonc.2023.1067234

8,193 views
4 citations

Review

Published on 23 Jan 2023

Sulforaphane: An emergent anti-cancer stem cell agent

in Cancer Molecular Targets and Therapeutics

Leandro de Lima Coutinho
Tharcísio Citrangulo Tortelli Junior
Maria Cristina Rangel

Frontiers in Oncology

doi 10.3389/fonc.2023.1089115

24,055 views
19 citations

Original Research

Published on 20 Jan 2023

HROP68: A rare case of medullary pancreatic cancer—characterization and chemosensitivity of the first patient-derived cell line

in Cancer Molecular Targets and Therapeutics

Jens von den Driesch
Jana Flöttmann
Friedrich Prall
Christina S. Mullins
Michael Linnebacher
Florian Bürtin

Frontiers in Oncology

doi 10.3389/fonc.2022.1082927

2,134 views
2 citations

Original Research

Published on 20 Jan 2023

14-3-3 and Smad2/3 are crucial mediators of atypical-PKCs: Implications for neuroblastoma progression

in Cancer Molecular Targets and Therapeutics

S. Breedy
W.S. Ratnayake
L. Lajmi
R. Hill
M. Acevedo-Duncan

Frontiers in Oncology

doi 10.3389/fonc.2023.1051516

2,223 views

Review

Published on 19 Jan 2023

The role of miR-128 in cancer development, prevention, drug resistance, and immunotherapy

in Cancer Molecular Targets and Therapeutics

Hendrik Setia Budi
Laith A. Younus
Methaq Hadi Lafta
Sameena Parveen
Hawraa Jabbar Mohammad
Zahraa Haleem Al-qaim
Mohammed Abed Jawad
Rosario Mireya Romero Parra
Yasser Fakri Mustafa
Firas Rahi Alhachami

Frontiers in Oncology

doi 10.3389/fonc.2022.1067974

3,878 views
26 citations

Mini Review

Published on 19 Jan 2023

Patient-derived models: Advanced tools for precision medicine in neuroblastoma

in Cancer Molecular Targets and Therapeutics

Kristina Aaltonen
Katarzyna Radke
Aleksandra Adamska
Alexandra Seger
Adriana Mañas
Daniel Bexell

Frontiers in Oncology

doi 10.3389/fonc.2022.1085270

4,459 views
6 citations

Original Research

Published on 18 Jan 2023

The BET inhibitor/degrader ARV-825 prolongs the growth arrest response to Fulvestrant + Palbociclib and suppresses proliferative recovery in ER-positive breast cancer

in Cancer Molecular Targets and Therapeutics

Ryan M. Finnegan
Ahmed M. Elshazly
Nipa H. Patel
Liliya Tyutyunyk-Massey
Tammy H. Tran
Vishnu Kumarasamy
Erik S. Knudsen
David A. Gewirtz

Frontiers in Oncology

doi 10.3389/fonc.2022.966441

3,958 views
13 citations

Original Research

Published on 16 Jan 2023

FOXO3 gene hypermethylation and its marked downregulation in breast cancer cases: A study on female patients

in Cancer Molecular Targets and Therapeutics

Mohammad Aasif Khan
Sadaf
Irfan Ahmad
Abdulaziz A. Aloliqi
Alaa Abdulaziz Eisa
Mohammad Zeeshan Najm
Maria Habib
Saad Mustafa
Sheersh Massey
Zoya Malik

Frontiers in Oncology

doi 10.3389/fonc.2022.1078051

2,814 views
3 citations

Navigation group

Articles

Identification of thioredoxin-1 as a biomarker of lung cancer and evaluation of its prognostic value based on bioinformatics analysis

Synthetic lethal interactions of DEAD/H-box helicases as targets for cancer therapy

Application of ddPCR in detection of the status and abundance of EGFR T790M mutation in the plasma samples of non-small cell lung cancer patients

HiRAND: A novel GCN semi-supervised deep learning-based framework for classification and feature selection in drug research and development

SLC-0111, an inhibitor of carbonic anhydrase IX, attenuates hepatoblastoma cell viability and migration

Krüppel-like factors in tumors: Key regulators and therapeutic avenues

GPBAR1 is associated with asynchronous bone metastasis and poor prognosis of hepatocellular carcinoma

Cancel cancer: The immunotherapeutic potential of CD200/CD200R blockade

COMMD proteins function and their regulating roles in tumors

Sulforaphane: An emergent anti-cancer stem cell agent

HROP68: A rare case of medullary pancreatic cancer—characterization and chemosensitivity of the first patient-derived cell line

14-3-3 and Smad2/3 are crucial mediators of atypical-PKCs: Implications for neuroblastoma progression

The role of miR-128 in cancer development, prevention, drug resistance, and immunotherapy

Patient-derived models: Advanced tools for precision medicine in neuroblastoma

The BET inhibitor/degrader ARV-825 prolongs the growth arrest response to Fulvestrant + Palbociclib and suppresses proliferative recovery in ER-positive breast cancer

FOXO3 gene hypermethylation and its marked downregulation in breast cancer cases: A study on female patients